Nexthera Capital’s Axsome Therapeutics AXSM Stock Holding History

Nexthera Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-400,000	Closed	-$1.56M	–	43
2017 Q1	$1.56M	Buy	+400,000	New	+$1.91M	0.8%	22

Other funds holding AXSM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

OPPM

Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return

Nexthera Capital's AXSM Position: Q2 2017 in Review

Nexthera Capital sold out of Axsome Therapeutics (AXSM) in Q2 2017, closing a stake of 400,000 shares — an estimated $1.56M sold.

Nexthera Capital first reported a position in AXSM in Q1 2017 and held it in 1 quarter. The position peaked at $1.56M in Q1 2017. 35 funds tracked by Wall St. Rank hold AXSM as of Q2 2017.

Nexthera Capital reported no remaining Axsome Therapeutics position as of Q2 2017 after selling out during the quarter.
Nexthera Capital sold 400,000 Axsome Therapeutics shares in Q2 2017, an estimated $1.56M.
Nexthera Capital first reported a position in Axsome Therapeutics in Q1 2017 and held it in 1 quarter.
Nexthera Capital's Axsome Therapeutics position peaked at $1.56M in Q1 2017.
35 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2017.

Based on Nexthera Capital's 13F filing for Q2 2017, filed 14 Aug 2017.